Molecular Diagnostics Markets in The COVID-19 Era

Molecular Diagnositcs Markets in The COVID-19 Era

Now more than ever, molecular diagnostics are the most important part of in vitro diagnostics. Kalorama Information has, for many years, estimated the size of and forecasted the growth of the worldwide market for molecular diagnostics in all major segments, and does so in this edition as a pandemic has reached developed markets including the United States.

2020 was set to be a year of growth and innovations in molecular diagnostics under any circumstances. New products, higher growth than other in vitro diagnostic categories, continued acceptance of next-generation sequencing methods were driving. Liquid biopsy technologies and the increased use of predictive genetic tests were and still are areas of anticipated revenue growth. The sudden onsent of SARS-CoV-2 and the resulting disease COVID-19 put the world’s focus on molecular diagnostics in an unexpected way.

This will not be universally the case. In non-COVID-19 testing areas, such as cancer and inherited diseases, molecular diagnostics vendors need to continue to persuade. Here volumes may be reduced by social distancing measures. But they are expected to continue to make progress converting laboratory customers. New technologies such as molecular near-patient and next-generation sequencing are increasingly part of the mix. The report details these trends.

This report provides 2020 market sizing and expected growth to 2025 for the following segments:

• COVID-19 Molecular IVD Test Market (Full Year 2020 Projected and Market 2H 2020)
• COVID-19 Molecular IVD Test Market North America
• COVID-19 Molecular IVD Test Market Europe
• COVID-19 Molecular IVD Test Market Asia Pacific
• COVID-19 Molecular IVD Test Market Rest of World
• Infectious Disease Markets, including:
• Hepatitis
• HIV
• Respiratory
• HAIs and Sepsis Tests
• TB
• Sexually Transmitted Diseases
• NAT Blood Testing
• Molecular Histology
• Molecular Cancer Testing
• Molecular Transplantation Testing
• Inherited Disease Testing
• NIPT
• Inherited
• Thrombophilia
• Pharmacogenomics

There has also been a huge influx of product introductions from small, obscure companies. These have mostly targeted the low end of the price range and often had poor performance, while a small number of high-end automated systems are mostly limited to certain segments of the market, such as independent reference laboratories and centralized hospital laboratories. Low-quality products from fly-by-night companies are the predictable result of the shortages and the relatively basic resources needed to produce mediocre antibody test kits with a low level of quality control. A few major companies are seeing the most test runs, particularly in the United States.

COVID-19 testing has also been a bit of a double-edged sword for labs generally, for in vitro diagnostics and for molecular tests. Boosting volumes in infectious disease have been notably paired with drops due to social distancing measures and hospital surgical postponements. What is the result? Kalorama Information’s report helps to sort out the array of news and reports about the current state of molecular diagnostics, reasonable global estimates for COVID, and the impact of COVID-19 on the rest of molecular testing.

Kalorama covers the global markets. For All Markets, Kalorama Information provides the following:

• Impacts of COVID-19 on Market Segments
• Regional Market Distribution
• Profiles of Top Companies
• Major Companies with COVID-19 Tests
• Other Companies with COVID-19 Tests
• HIV Products on the Market
• Transplantation Products on the Market
• The Increasing Role of Next-Generation Sequencing
• Trends – Lab Automation and Molecular Diagnostics
• Trends – CRISPR
• Trends – Artificial Intelligence
• Company Profiles

Kalorama Information has monitored 2020 secondary sources, trade publications, medical journals, government websites and policy documents, as well as financial statements from vendors to assess the market impact of COVID-19. In addition, Kalorama has been tracking lab volumes with a survey since mid-April, and Kalorama’s U.S. MasterFile product was used to keep track of instrument trends.

Companies Profiled in the Report Include

• Abbott Diagnostics
• Agena Bioscience
• Agendia BV
• ARUP Laboratories
• Asuragen
• Advanced Cell Diagnostics
• Agilent
• Amoy Diagnostics
• Applied Spectral Imaging
• Becton, Dickinson & Co.
• Biocartis
• BGI
• Berry Genomics
• BioMerieux
• Bio-Rad
• Care DX
• Danaher
• Cepheid
• Beckman Coulter
• Leica Biosystems
• Eiken Chemical
• Fluidigm
• GenMark
• Genotypic Technology PVT
• Greiner Bio-One GMBH
• Grifols
• Hologic
• Illumina
• Immucor
• Meridian
• Molbio
• Myriad Genetics
• Nanostring
• Neogenomics
• NeuromoDX
• Perkin Elmer
• Oxford Nanopore
• Promega
• Prescient Medicine
• Qiagen
• Quidel
• Roche
• Thermo
• Vela
• Veracyte